This content is for ESMO members only.

Login

Learn more about how you can join ESMO

Presentation

Download slides

Programme

2 April 2025

Welcome and introduction

Solange Peters

Beyond PD-1 axis inhibition

Martin Reck

ADCs – designer drugs?

Egbert Smit

Targeting the microbiome

Bertrand Routy

QnA and Discussion

All speakers

Solange Peters
Chair

Centre Hospitalier Universitaire Vaudois (CHUV)
Oncology Department,
Lausanne
Martin Reck
Speaker

Department of Thoracic Oncology
Lung Clinic Grosshansdorf
Grosshansdorf
Egbert Smit
Speaker

Netherlands Cancer Institute
Bertrand Routy
Speaker

Associate professor of Hemato-Oncology, University of Montreal (CHUM)
Director of the CHUM Microbiome Centre
University of Montreal Research Centre (CRCHUM)

Description

This ESMO Deep Dive Lung Cancer Webinar focused on Advanced NSCLC - Non-oncogene Addicted.

ADCs, immunotherapy, and the microbiome represent critical advancements in the treatment of advanced NSCLC emerging in the 2010s. ADCs offer targeted cytotoxic therapy by delivering potent chemotherapeutic agents directly to cancer cells while minimizing systemic toxicity. Immunotherapy, particularly immune checkpoint inhibitors targeting PD-1/PD-L1, has transformed NSCLC management by enhancing anti-tumor immune responses, improving survival, and offering durable remissions in select patients. Emerging evidence also suggests that the gut microbiome modulates immunotherapy efficacy, influencing response rates and toxicity profiles. Understanding these evolving therapeutic strategies is essential for optimizing patient outcomes and advancing personalized treatment approaches in NSCLC.

Learning objectives

To acquire a deeper understanding of the clinical course of malignant disease of lung cancer.
To understand biological hypotheses on classification and risk stratification, ongoing/required research in therapeutics and knowledge of use of omics technologies for biomarker-enabled precision medicine for lung cancer.
To develop skills and abilities for critical analysis, interpretation of research data and therapeutic strategies.
To become better equipped for informed, innovative thinking and engagement in ongoing or new research projects.

Solange Peters
Chair

Centre Hospitalier Universitaire Vaudois (CHUV)
Oncology Department,
Lausanne
Martin Reck
Speaker

Department of Thoracic Oncology
Lung Clinic Grosshansdorf
Grosshansdorf
Egbert Smit
Speaker

Netherlands Cancer Institute
Bertrand Routy
Speaker

Associate professor of Hemato-Oncology, University of Montreal (CHUM)
Director of the CHUM Microbiome Centre
University of Montreal Research Centre (CRCHUM)

This content is for ESMO members only.

Presentation

Programme

Description

Learning objectives

Supported by

You may also be interested in...